Lilly sues to stem black-market retatrutide ahead of 2027 filing

Eli Lilly filed lawsuits on Wednesday against six U.S. companies, including compounding pharmacies and medical spas, for selling unapproved versions of its experimental weight-loss drug, retatrutide. The defendants—Aesthetic Envy Cosmetic Centers, Astra LLC, Legendary Peptides, Striker Pharmacy, Texas Peptides, and Lone Star Peptide Co.—are accused of offering a compound that has not been cleared for human use by any regulatory agency.

For investors, the legal action underscores the immense pent-up demand for Lilly’s next-generation obesity treatments, as well as the risks to its brand equity before the drug even reaches the market. Retatrutide is widely considered a blockbuster candidate after five late-stage trials showed participants losing an average of 28.3% of their body weight over 80 weeks on the highest dose.

The illicit market for GLP-1 drugs has surged dramatically. U.S. Customs and Border Protection seized more than 690 shipments of these drugs, totaling over 31,000 units, in fiscal year 2025. In July alone, agents intercepted close to 90,000 vials across more than 1,400 seizures, illustrating the scale of the underground supply chain.

Lilly is moving beyond the courtroom to dismantle this network. The drugmaker has flagged over 200 entities to federal and state authorities and reported more than 14,000 websites, social media posts, and product listings across 100 countries. "What is being sold on the black market is not a medicine — it is entirely unverified, unapproved and not worth the risk," said Dr. David A. Hyman, Lilly’s chief medical officer. "Every single time that someone takes one of these, they're exposing themselves to a huge amount of risk," added Dr. Max Denning, the company's associate vice president for global patient safety in cardiometabolic health.

The black-market rush highlights a supply gap that will persist longer than initially expected. Lilly revealed last month that it will not seek FDA approval for retatrutide until the first quarter of 2027, abandoning a previous target of late this year. The drugmaker attributed the revised timeline to the additional time needed to compile manufacturing and quality-control data.

To bridge part of that gap, Lilly confirmed earlier this month it will grant limited early access to retatrutide for patients meeting strict medical criteria. In the meantime, eradicating unregulated sellers remains a priority, as the FDA has stated the drug cannot legally be compounded and vendors often falsely label foreign-sourced vials as being for "research use only."